Foundation Medicine Obtains FDA Approval For Non Small Cell Lung Cancer Companion Diagnostic
Executive Summary
Foundation Medicine and Novartis’ commercial partnership has achieved another success as Foudation’s Liquid CDx is approved.
You may also be interested in...
Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test
Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.
Guardant Health, Roche’s Foundation Medicine Receive FDA Companion Diagnostic Nods
Roche’s Foundation Medicine still leads Guardant Health in terms of total companion-diagnostic US FDA approvals as both companies announced new PMA supplements.
Novartis Tabrecta Is First Treatment For NSCLC With METex14 Mutation
The US FDA granted an accelerated approval for the lung cancer treatment targeting a mutation found in only about 4,000-5,000 NSCLC patients in the US each year.